Published in Inflammopharmacology on January 01, 2005
The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis (2006) 1.27
COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status. BMC Cancer (2011) 0.89
High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int J Colorectal Dis (2008) 0.87
PAX2 protein induces expression of cyclin D1 through activating AP-1 protein and promotes proliferation of colon cancer cells. J Biol Chem (2012) 0.83
Disease Comorbidity Network Guides the Detection of Molecular Evidence for the Link Between Colorectal Cancer and Obesity. AMIA Jt Summits Transl Sci Proc (2015) 0.81
[6]-Gingerol induces caspase-dependent apoptosis and prevents PMA-induced proliferation in colon cancer cells by inhibiting MAPK/AP-1 signaling. PLoS One (2014) 0.80
HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Lett (2013) 0.79
Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway. Biomed Res Int (2015) 0.79
Crosstalk between Wnt Signaling and RNA Processing in Colorectal Cancer. J Cancer (2013) 0.78
Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901. World J Gastroenterol (2008) 0.78
Engineering pre-SUMO4 as efficient substrate of SENP2. Protein Eng Des Sel (2014) 0.78
Short hairpin RNA screen indicates that Klotho beta/FGF19 protein overcomes stasis in human colonic epithelial cells. J Biol Chem (2011) 0.77
SCF/C-Kit/JNK/AP-1 Signaling Pathway Promotes Claudin-3 Expression in Colonic Epithelium and Colorectal Carcinoma. Int J Mol Sci (2017) 0.75
FosB transcription factor regulates COX-2 expression in colorectal cancer cells without affecting PGE2 expression. Oncol Lett (2017) 0.75
Polymorphism of the p38β gene in patients with colorectal cancer. Oncol Lett (2014) 0.75
STAT1 modification improves therapeutic effects of interferons on lung cancer cells. J Transl Med (2015) 0.75
Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality. Cell Cycle (2016) 0.75
Time course analysis based on gene expression profile and identification of target molecules for colorectal cancer. Cancer Cell Int (2016) 0.75
Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Ann Oncol (2016) 0.75
Chloroquine inhibits human CD4(+) T-cell activation by AP-1 signaling modulation. Sci Rep (2017) 0.75
Activator protein-1 (AP-1): a bridge between life and death in lung epithelial (A549) cells under hypoxia. Mol Cell Biochem (2017) 0.75
Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia. Oncogene (2017) 0.75
Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell (1987) 20.61
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta (1991) 11.78
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (2000) 8.56
NF-kappa B: a lesson in family values. Cell (1995) 7.33
AP-1 in cell proliferation and survival. Oncogene (2001) 6.07
Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature (1988) 5.18
Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci U S A (1987) 4.96
Colorectal cancer. Lancet (1999) 4.72
Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. Proc Natl Acad Sci U S A (1983) 4.38
Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A (1999) 4.35
Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell (1989) 4.17
Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature (1991) 4.17
AP-1 in mouse development and tumorigenesis. Oncogene (2001) 3.93
c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J (1999) 3.65
c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell (1996) 3.54
Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev (1999) 3.51
Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J (1993) 3.28
A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev (1993) 3.21
A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron (1995) 3.11
The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol (1991) 3.08
Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol (1994) 2.75
c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature (1994) 2.16
Genomic instability and colon cancer. Cancer Metastasis Rev (2004) 2.15
Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts. Nature (1988) 2.12
Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene (1993) 2.07
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol (1999) 2.00
Functions of c-Jun in liver and heart development. J Cell Biol (1999) 1.85
The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell (2000) 1.81
Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene (1994) 1.81
Molecular biology of colorectal cancer. Curr Probl Cancer (1998) 1.70
c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem (1999) 1.58
Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island. J Biol Chem (1999) 1.54
cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene (1999) 1.42
Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol (1994) 1.39
Progression of diabetic nephropathy. Am J Kidney Dis (2003) 1.38
Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res (1997) 1.36
Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer (2000) 1.32
Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res (2003) 1.24
Transcription factors and asthma. Eur Respir J (1998) 1.23
Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol Med (2003) 1.21
Sequence of molecular genetic events in colorectal tumorigenesis. Eur J Cancer Prev (1999) 1.18
c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol (2000) 1.18
The role of bile acids in carcinogenesis. Mutat Res (2001) 1.17
Protective role for c-Jun in the cellular response to DNA damage. J Biol Chem (2001) 1.12
Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression. Growth Factors (2001) 1.11
AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene (2001) 1.10
Cell proliferation and cell cycle progression are not impaired in fibroblasts and ES cells lacking c-Fos. Oncogene (1995) 1.09
Inhibition of c-jun causes reversible proliferative arrest and withdrawal from the cell cycle. Blood (1992) 1.08
Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes. Mol Carcinog (2000) 1.05
Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res (1998) 1.00
Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther (2004) 0.99
Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats. Gene Ther (2001) 0.97
In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. Gastroenterology (1997) 0.96
Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells. J Clin Lab Anal (1995) 0.95
Gene therapy for colon cancer. Hematol Oncol Clin North Am (1998) 0.90
Molecular targets of the oncogenic transcription factor jun. Curr Cancer Drug Targets (2003) 0.87
Brain injury: prolonged induction of transcription factors. Acta Neurobiol Exp (Wars) (2000) 0.87
Effects of dominant-negative c-Jun on platelet-derived growth factor-induced vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol (2002) 0.86
Transcriptional repression of p21((Waf1/Cip1/Sdi1)) gene by c-jun through Sp1 site. Biochem Biophys Res Commun (2000) 0.84
Expression of Jun family members in human colorectal adenocarcinoma. Carcinogenesis (2000) 0.83
Gene therapy for colorectal cancer. Br Med Bull (2002) 0.79
Gene therapy strategies for colon cancer. Mol Med Today (2000) 0.79
Effects on Cell Proliferation, Activator Protein-1 and Genotoxicity by Fecal Water from Patients with Colorectal Adenomas. Scand J Gastroenterol (2003) 0.75
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
A comprehensive genetic map of the cattle genome based on 3802 microsatellites. Genome Res (2004) 2.38
Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc (2013) 2.30
Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol (2014) 2.30
Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol (2009) 2.05
Use of three-dimensional computed tomographic angiography of pulmonary vessels for lung resections. Ann Thorac Surg (2003) 2.03
A prospective, single-blind trial comparing wireless capsule endoscopy and double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. J Gastroenterol (2008) 2.02
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg (2009) 2.02
Comparative study of conventional colonoscopy and pan-colonic narrow-band imaging system in the detection of neoplastic colonic polyps: a randomized, controlled trial. J Gastroenterol (2008) 2.00
Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol (2009) 1.89
Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol (2010) 1.80
Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol (2003) 1.77
Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol (2004) 1.77
Core protein of hepatitis C virus induces cardiomyopathy. Circ Res (2004) 1.73
Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol (2008) 1.71
Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol (2009) 1.70
Spontaneous hemothorax in neurofibromatosis treated with percutaneous embolization. Cardiovasc Intervent Radiol (2007) 1.64
Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. Gastrointest Endosc (2012) 1.62
Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients. AJR Am J Roentgenol (2005) 1.58
Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res (2003) 1.58
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol (2007) 1.56
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat (2011) 1.55
Association between gastroesophageal flap valve, reflux esophagitis, Barrett's epithelium, and atrophic gastritis assessed by endoscopy in Japanese patients. J Gastroenterol (2003) 1.55
Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2008) 1.54
Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study. Clin Drug Investig (2006) 1.51
Genome-wide analysis of epigenomic alterations in fetal mouse forebrain after exposure to low doses of bisphenol A. Biochem Biophys Res Commun (2008) 1.51
Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol (2003) 1.51
Efficacy and safety of balloon-occluded endoscopic injection sclerotherapy as a prophylactic treatment for high-risk gastric fundal varices: a prospective, randomized, comparative clinical trial. Gastrointest Endosc (2002) 1.51
Admission hyperglycemia is an independent predictor of acute kidney injury in patients with acute myocardial infarction. Circ J (2014) 1.49
Cross-breed comparisons identified a critical 591-kb region for bovine carcass weight QTL (CW-2) on chromosome 6 and the Ile-442-Met substitution in NCAPG as a positional candidate. BMC Genet (2009) 1.47
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med (2013) 1.46
Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation (2002) 1.45
TIPS versus transcatheter sclerotherapy for gastric varices. AJR Am J Roentgenol (2004) 1.42
A comprehensive radiation hybrid map of the bovine genome comprising 5593 loci. Genomics (2005) 1.41
Flat colorectal neoplasms and the impact of the revised Vienna Classification on their reporting: a case-control study in UK and Japanese patients. Scand J Gastroenterol (2006) 1.41
Possible involvement of adrenomedullin in lipopolysaccharide-induced small-intestinal motility changes in conscious rats. J Gastroenterol (2005) 1.39
Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol (2006) 1.33
Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology (2006) 1.31
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A (2010) 1.30
Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg (2002) 1.29
Genome-wide association study identified three major QTL for carcass weight including the PLAG1-CHCHD7 QTN for stature in Japanese Black cattle. BMC Genet (2012) 1.28
Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol (2008) 1.28
The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J Exp Med (2003) 1.28
A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol (2003) 1.27
Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. J Pharmacol Sci (2009) 1.27
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res (2012) 1.26
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat (2006) 1.25
Effect of chronic stress on gastric emptying and plasma ghrelin levels in rats. Life Sci (2008) 1.20
Management of gastric fundal varices without gastro-renal shunt in 15 patients. World J Gastroenterol (2008) 1.19
15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci (2005) 1.19
Overexpression of the Runx3 transcription factor increases the proportion of mature thymocytes of the CD8 single-positive lineage. J Immunol (2005) 1.17
Protein phosphatase 4 catalytic subunit regulates Cdk1 activity and microtubule organization via NDEL1 dephosphorylation. J Cell Biol (2008) 1.17
Identification of bovine QTL for growth and carcass traits in Japanese Black cattle by replication and identical-by-descent mapping. Mamm Genome (2007) 1.17
Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci (2008) 1.16
Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol (2009) 1.16